Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning,...

Full description

Bibliographic Details
Main Author: Brent L. Rollins
Format: Article
Language:English
Published: Kerman University of Medical Sciences 2016-04-01
Series:International Journal of Health Policy and Management
Subjects:
Food and Drug Administration (FDA)
Direct-to-Consumer Advertising (DTCA)
Notice of Violations (NOV)
Office of Prescription Drug Promotion (OPDP)
Fair Balance
Online Access:http://www.ijhpm.com/pdf_3159_c3eba2a1569361b654b9856b57228c65.html

Internet

http://www.ijhpm.com/pdf_3159_c3eba2a1569361b654b9856b57228c65.html

Similar Items